Furthermore, our results demonstrate that patients with hormone receptor-negative (ER/PR) status are most likely to exhibit higher KPNA2 mRNA expression levels, in comparison to patients with hormone receptor-positive breast cancers (P < 0.0001, Fig. 1). This evidence concerns the gene PGR and breast carcinoma.